Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -21,884 | -15,515 | -6,767 | -25,745 | -18,212 |
| Depreciation Amortization | 165 | 102 | 47 | 172 | 117 |
| Accounts receivable | 97 | 104 | -9 | -101 | 81 |
| Other Working Capital | -482 | -2,183 | -707 | -6,765 | -7,333 |
| Other Operating Activity | 3,280 | 3,174 | 1,434 | 2,444 | 1,325 |
| Operating Cash Flow | $-18,825 | $-14,318 | $-6,003 | $-29,995 | $-24,022 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -396 | -335 | -169 | -75 | -31 |
| Investing Cash Flow | $-396 | $-335 | $-169 | $-75 | $-31 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -9,075 | -9,075 |
| Common Stock Issued | 677 | 670 | 430 | 363 | 337 |
| Other Financing Activity | 73,891 | 0 | 0 | 54,496 | 22,791 |
| Financing Cash Flow | $74,568 | $670 | $430 | $45,784 | $14,053 |
| Exchange Rate Effect | 511 | 648 | 96 | -1,955 | -680 |
| Beginning Cash Position | 33,101 | 33,101 | 33,101 | 19,342 | 19,342 |
| End Cash Position | 88,959 | 19,766 | 27,455 | 33,101 | 8,662 |
| Net Cash Flow | $55,858 | $-13,336 | $-5,647 | $13,760 | $-10,680 |
| Free Cash Flow | |||||
| Operating Cash Flow | -18,825 | -14,318 | -6,003 | -29,995 | -24,022 |
| Capital Expenditure | -396 | -335 | -169 | -104 | -60 |
| Free Cash Flow | -19,221 | -14,654 | -6,172 | -30,099 | -24,082 |